Builds MRI machines with built-in helium recycling systems that lock hospitals into facility-specific setups they cannot easily replace.
What this company is and how it runs — written from structure, not news.
Novoray Corp. builds MRI superconducting magnets with helium-recycling systems engineered directly into the magnet housing, so the cooling loop and the physical geometry of the machine are a single inseparable unit. Because the housing geometry controls the recycling loop's pressure dynamics, a hospital installing one of these machines must reinforce its imaging suite and install custom electromagnetic shielding sized to that exact magnet — a commitment of $200,000 or more in room construction before the first scan runs. Once that work is done and the FDA has issued clearance for that specific device running those specific protocols, replacing the magnet means rebuilding the room, resubmitting clinical validation data, and retraining staff for six to twelve months, so the real switching cost is not the machine but the facility and the regulatory clock. The same integration that creates that lock-in is also the company's exposure: if helium supply disruptions from Qatar or Russia erode the cost advantage of recycling over simply venting helium, hospitals facing cost parity may decide the rebuild and revalidation are worth it to move to a simpler competitor, and the recycling loop's role as the anchor of the whole arrangement disappears with it.
How does this company make money?
The company sells MRI machines for between $1 million and $3 million each and CT scanners for between $500,000 and $2 million each. After the sale, it earns recurring revenue through multi-year service contracts that cover the ongoing liquid helium supply, routine maintenance, and software updates — keeping the company involved with every machine for years after it ships.
What makes this company hard to replace?
Before a hospital can even turn on one of these machines, it must spend $200,000 or more reinforcing the room and installing custom electromagnetic shielding sized to this specific magnet. Staff then spend 6 to 12 months learning the imaging protocols and software well enough to produce reliable diagnostic results. On top of that, the FDA clearance on file covers this exact device running these exact protocols — swapping in a different machine means filing new clinical validation data and waiting for fresh approval, with no guarantee of how long that takes.
What limits this company?
Each magnet must be wound with niobium-titanium wire, fitted with its helium cooling system, and then tested individually for electromagnetic uniformity — all inside specially shielded manufacturing bays. Those bays cannot be expanded infinitely or the work handed off to outside suppliers, so the number of units the company can ship in any period is capped directly by how many of those shielded bays it has and how many magnets fit through them.
What does this company depend on?
The company cannot operate without liquid helium for magnet cooling, niobium-titanium superconducting wire for the magnets themselves, rare earth elements for the gradient coil magnets, specialized X-ray tubes for CT scanner gantries, and FDA 510(k) clearance for each device model it sells.
Who depends on this company?
Hospital radiology departments rely on these machines to detect strokes and cancer — if the units failed, that diagnostic capacity would stop. Emergency departments use CT scanners to assess head injuries in trauma cases and would lose that capability immediately. Medical research institutions running clinical trials depend on consistent imaging protocols; without them, patient enrollment would stall.
How does this company scale?
Once image reconstruction algorithms and diagnostic software protocols are built, they can be copied onto every additional machine at almost no cost. What does not scale easily is the physical manufacturing: every superconducting magnet still needs its own helium cooling commissioning and its own electromagnetic homogeneity test, by hand, in a shielded bay. Software grows cheaply; magnets do not.
What external forces can significantly affect this company?
Helium supply is vulnerable to disruptions in Qatar and Russia, which are major producers — any production constraint drives up the cooling costs the recycling system is designed to reduce. Medicare reimbursement rate cuts for diagnostic imaging reduce the revenue hospitals earn per scan, which shrinks the budgets they have for buying or replacing capital equipment like MRI and CT machines. Import restrictions on rare earth elements from China could limit the availability of materials needed for gradient coil magnets.
Where is this company structurally vulnerable?
If helium production from Qatar or Russia is severely disrupted and prices spike, hospitals would start comparing the ongoing cost of running this company's recycling system against the one-time cost of rebuilding the room and revalidating with a simpler vented competitor. If that comparison ever tips in the competitor's favor, the recycling system stops being the reason hospitals stay — and the entire lock-in mechanism unravels.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in4 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Three observations have aligned in the up direction: the Ichimoku-cloud composite is firing on its up-side configuration, the trend-strength composite is in the upper portion of its mapped range, and the volume-weighted-returns sum over the 60-week lookback is net positive.
Three observations describe the present configuration: a high share of the trailing year's weekly closes were higher than the prior week, the company has reported positive net income in each of the last three annual periods, and the industry-benchmarked TTM operating cash flow margin is in the upper peer range.
Three observations have aligned: ADX directional-movement asymmetry is elevated, the volume-weighted returns observation is net positive over its lookback, and OBV is trending up over its lookback. The volume observation point up; ADX itself is direction-agnostic.
Three observations have aligned: the magnitude of difference between recent (10-week) and long-run (52-week) annualized volatility is high, recent 10-week ATR is above its prior 10-week window, and 20-week annualized volatility is in the upper portion of its mapped range.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
11 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Three margin observations have aligned: industry-benchmarked gross profit margin is in the upper peer range, operating income margin is in the upper portion of its mapped range, and industry-benchmarked TTM operating cash flow margin is in the upper peer range.
Three observations describe the present configuration: operating income increased year-over-year in each of the last four fiscal years, the 6-year revenue CAGR is positive, and revenue increased year-over-year in each of the last five fiscal years. None of the three observations divides by revenue.
Three margin observations have aligned: industry-benchmarked gross profit margin is in the upper peer range, operating income margin is in the upper portion of its mapped range, and industry-benchmarked net profit margin is in the upper peer range.
Four observations co-occur: free cash flow positive each of the last three fiscal years, revenue increased each of the last three fiscal years, trailing-statistics OCF margin elevated, and book value increased each of the last four fiscal years. The configuration describes multi-year fundamental persistence across cash flow, top line, margin, and equity accumulation.
Three observations co-occur: free cash flow has been positive each of the last three fiscal years, ADX directional-movement asymmetry is elevated, and the 50-week SMA sits above the 200-week SMA. The set describes past free-cash-flow generation alongside lopsided directional movement and a present-state price/SMA geometry.
Is this company growing?
Three observations from different domains align: revenue has grown on a 6-year compound basis, net income has grown on a 6-year compound basis, and the 60-week sum of volume-weighted returns is net positive. Together they describe multi-year fundamental compounding alongside positive volume-weighted price action.
Three growth observations align: net income CAGR over the trailing 6 years is positive, revenue CAGR over the trailing 6 years is positive, and a growth-consistency composite reads high. Together they describe a multi-year compound-growth pattern.
Three multi-year observations co-occur: revenue increased year-over-year in each of the last three fiscal years, gross profit (absolute level) increased year-over-year in each of the last four fiscal years, and net income was positive in each of the last five fiscal years. The configuration describes growth-and-profitability persistence across three different windows.
How is this stock valued?
Three observations describe the present configuration: the most recent run of consecutive down-close weeks is at or near the configured ceiling, the company has reported positive net income in each of the last three annual periods, and the industry-benchmarked equity ratio is in the upper range against peers.
Retained earnings are a large share of total assets; net income was positive in each of the last 5 fiscal years; shareholders' equity is in the upper part of its industry's equity-to-assets range.
Where is this company structurally exposed?
Three price-behavior observations have aligned: the ulcer index (drawdown depth and duration composite) is elevated, current drawdown from peak is significant, and 20-week annualized volatility is in the upper portion of its mapped range.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
Follow hydrocarbons through cracking, separation, polymers, conversion, use, and recovery. A cracker produces a coupled slate, so feedstock, product demand, contracts, plant configuration, and waste routes constrain one another.
Follow feedstock through monomer and polymer production, compounding, conversion, packaging, use, collection, recycling, combustion, and disposal. Resin tonnes and recycling rates are bounded measurements, not proof that the original function returned.
Follow natural rubber from tree and tapping through coagulation, grading, compounding, vulcanization, service, and recovery. The chain preserves some properties while closing others, and money arrives on a faster clock than a new stand of trees.
CompanyGraph